What it sells
Genetic Medicine with Small Molecules
Business model breakdown
Buyer: who owns the budget?
Biotech and pharma R&D teams (the partners page lists pharma collaborators; Chiesi Group signed a respiratory-disease deal in July 2025).
Trigger: what makes them buy now?
Partners bring hard, previously undruggable targets that protein-centric small-molecule discovery cannot reach.
Workflow: what inputs become what output?
AI-native pipeline: target discovery from an atlas of 200,000+ RNA pockets, hit discovery by screening RNA-small molecule libraries, then AI-driven lead optimization.
Economics: what it saves and how it charges
Drug-discovery collaborations: Chiesi deal pays success-based near-term payments, future milestone payments, single-digit deferred contingent payments and commercial milestones on product sales.
Distribution: how it reaches customers
Partnering: target validation, co-development programs, platform access/licensing (Orion, Polaris, Ara) and data licensing.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.